HLA polymorphism and risk of multiple myeloma

Leukemia

Volumn 30, Issue 11, 2016, Pages 2260-2264

  Beksac, M ^a   Gragert, L ^b,c   Fingerson, S ^b,c   Maiers, M ^b,c   Zhang, M J ^d   Albrecht, M ^b,c   Zhong, X ^d   Cozen, W ^e   Dispenzieri, A ^f   Lonial, S ^g   Hari, P ^d  

^a ANKARA UNIVERSITY   (Turkey)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ALLELE; ASIAN; CANCER RISK; CAUCASIAN; GENETIC POLYMORPHISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISPANIC; HLA SYSTEM; HLA TYPING; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; UNITED STATES; ADULT; AGED; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

HLA ANTIGEN;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84994355363     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.199     Document Type: Letter

References (20)

1. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114: 785-790.
2. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904-906.
3. Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol 2002; 38: 1039-1049.
4. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet 2013; 14: 301-323.
5. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A et al. Common variation at 3q26. 2, 6p21. 33, 17p11. 2 and 22q13. 1 influences multiple myeloma risk. Nat Genet 2013; 45: 1221-1225.
6. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21. 32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011; 7: e1001378.
7. Ludwig H, Mayr W. Genetic aspects of susceptibility to multiple myeloma. Blood 1982; 59: 1286-1291.
8. Gragert L, Fingerson S, Albrecht M, Maiers M, Kalaycio M, Hill BT. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 2014; 124: 2657-2665.
9. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens 2012; 80: 1-11.
10. Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Human Immunol 2013; 74: 1313-1320.
11. Fabrigar LR, Wegener DT. Exploratory Factor Analysis (Understanding Statistics). Oxford University Press, 2011.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological) 1995; 57: 289-300.
13. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011; 472: 495-498.
14. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 2005; 54: 172-178.
15. Alcoceba M, Sebastian E, Marin L, Balanzategui A, Sarasquete ME, Chillon MC et al. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood 2013; 122: 1448-1454.
16. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood 2010; 115: 4820-4823.
17. Preuss KD, Pfreundschuh M, Fadle N, Regitz E, Raudies S, Murwaski N et al. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A. Blood 2011; 118: 3340-3346.
18. Preuss KD, Pfreundschuh M, Weigert M, Fadle N, Regitz E, Kubuschok B. Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor. J Clin Invest 2015; 125: 2179.
19. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 2016; 374: 555-561.
20. Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KM, Groen R et al. Optimal selection of natural killer cells to kill myeloma: The role of HLA-E and NKG2A. Cancer Immunol Immunother 2015; 64: 951-963.